Jaroslav Roh

Associate Professor

Charles University, Faculty of Pharmacy in Hradec Kralove

Czech Republic

Research Interests

Explore related searches

Professors in Organic Chemistry

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jaroslav Roh is an Associate Professor at Charles University, Faculty of Pharmacy in Hradec Kralove, Czech Republic. His research focuses on the design and synthesis of novel pharmacological agents, particularly in the fields of antitubercular and anticancer activity. Recent publications include investigations into iron-chelating agents for neuroprotection and the development of water-soluble prodrugs for cardioprotective applications against anthracycline cardiotoxicity.

Articles (12)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (5)

Miloslav Macháček

Charles University

CZECH REPUBLIC

View details

Tomas Simunek

Professor, Vice-Dean

Charles University

CZECH REPUBLIC

View details

Vojtech Spiwok

University of Chemistry and Technology

CZECH REPUBLIC

View details

Jan Korabecny

National Institute of Mental Health

CZECH REPUBLIC

View details

Jozef Nosek

CZECH REPUBLIC

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jaroslav Roh

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1

Pyrimidine derivatives with antitubercular activity

The UHPLC-UV method applied for the forced degradation study of ixazomib and HRMS identification of its degradation products

Proline, hydroxyproline, and pyrrolidone carboxylic acid derivatives as highly efficient but reversible transdermal permeation enhancers

7-Azaindole, 2,7-diazaindole, and 1<i>H</i>-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties

Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine

Design and Synthesis of Pyrano[3,2-b]indolones Showing Antimycobacterial Activity

Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity

Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions

Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation

Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo

Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II beta Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity

Collaborators (5)

Miloslav Macháček

Tomas Simunek

Vojtech Spiwok

Jan Korabecny

Jozef Nosek

Make your next move.